Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 22, 2023

Investigational Drug Information for CP1-1189

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug CP1-1189?

CP1-1189 is an investigational drug.

There have been 4 clinical trials for CP1-1189. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1^st 2009.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are National Cancer Institute (NCI), H. Lee Moffitt Cancer Center and Research Institute, and Sheba Medical Center.

Summary for CP1-1189

US Patents	0
International Patents	0
US Patent Applications	251
WIPO Patent Applications	111
Japanese Patent Applications	89
Clinical Trial Progress	Phase 2 (2009-07-01)
Vendors	42

Recent Clinical Trials for CP1-1189

Title	Sponsor	Phase
A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects	EA Pharma Co., Ltd.	Early Phase 1
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation	Sheba Medical Center	Phase 2
Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)	University of Leipzig	Phase 1/Phase 2

See all CP1-1189 clinical trials

Clinical Trial Summary for CP1-1189

Top disease conditions for CP1-1189

Top clinical trial sponsors for CP1-1189

See all CP1-1189 clinical trials

US Patents for CP1-1189

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

Moodys

Merck

Colorcon

Boehringer Ingelheim

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.